Project Grant HT9425261E387
- Federal Project Grant Award Summary Emory University received a $3.13 million project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded May 1, 2025, with a completion date of April 30, 2029. The award supports therapeutic research focused on the development and application of human induced pluripotent stem cell-derived lymphatic endothelial cells for treating lymphedema. This four-year research initiative will be...
- Federal Grant Award Summary Emory University's Office of Sponsored Programs received a $585,759 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2028. The research project, "Targeting GPNMB to Improve Efficacy of CDK4/6 Inhibitors in ER+ Breast Cancer," will be conducted at Emory's Atlanta, Georgia campus. This three-year award supports advanced biomedical...
- Federal Project Grant Award Summary Emory University's Office of Sponsored Programs received a $2,099,227 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026, through August 31, 2029. The award funds investigative research titled "Investigating the Dark Proteome of Advanced Prostate Cancer," with research activities conducted at Emory's Atlanta, Georgia campus. This three-year...
- Federal Grant Award Summary Emory University's Office of Sponsored Programs received a $156,049 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period October 1, 2025, through September 30, 2026. The project, titled "Establishing Epigenetic Markers in Neurofibromatosis," supports biomedical research designed to advance innovative medical solutions for military service members and the American public....
- Federal Project Grant Summary Emory University's Office of Sponsored Programs received a $840,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective April 1, 2026, through March 31, 2028. The award funds research to develop repurposed approved drugs as first-in-class disruptors of the P38/MK2 complex to suppress neuroinflammation in amyotrophic lateral sclerosis (ALS). This investigator-initiated...
- Federal Grant Award Summary Emory University's Office of Sponsored Programs received a $1.48M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2025, and concluding August 31, 2029. The ELECTRIG project will evaluate the effects of cranial electrical stimulation therapy with responsive imaging in Gulf War Illness pain and comorbid symptoms. This research directly supports the DHA's mission to...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Beckman Research Institute of the City of Hope a $1.4 million Project Grant on August 31, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research targeting aberrant end-joining repair for improving treatment of mixed phenotype acute leukemia. The three-year project, which extends through July 31, 2029, will be conducted at the Institute's research facility in Irwindale, California....
- Federal Grant Award Summary New York University School of Medicine received a $750,962 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 15, 2026 through June 14, 2029. The award supports a three-year research initiative titled "Neoadjuvant Checkpoint and IL-6 Blockade: Mechanisms of Benefit and Toxicity," which investigates the mechanisms underlying immunotherapy benefit and...
- This federal Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) provides $568,687 to Emory University to develop novel radiogenomic tools for predicting outcomes for small cell lung cancer patients treated with chemoimmunotherapy. The project, with a performance period from February 1, 2024 to January 31, 2027, aims to advance scientific knowledge and improve clinical outcomes in this patient population through...
- Federal Project Grant Award Summary Award: The Defense Health Agency (DHA), through its Military Medical Research and Development program (CFDA 12.420), awarded Duke University's Office of Research Administration a Project Grant of $564,705 on September 15, 2025, for research extending through September 14, 2028. The award supports the identification of oncofusion-interacting proteins as essential drug targets for common and rare oncofusions in rhabdomyosarcoma. This research initiative aligns...
Emory University's Office of Sponsored Programs received a $1.62M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2029. The award funds investigator-initiated research on chemotherapy induction regimens for lineage switch acute myeloid leukemia (LS-AML) or mixed phenotype acute leukemia (LS-MPAL) occurring post-ALL (acute lymphoblastic leukemia)-directed immunotherapy. This research addresses a critical clinical gap in treating patients who experience lineage switching as a complication of immunotherapy, with the goal of developing optimized therapeutic strategies for this rare and challenging disease presentation. The three-year award supports basic and translational research activities conducted at Emory's Atlanta, Georgia campus, consistent with DHA's portfolio of awards spanning oncology, hematology, and immunotherapy-related complications affecting military service members and the broader patient population. The research aligns with the Military Medical Research and Development program's mission to advance innovative biomedical solutions addressing unmet clinical needs through competitive, peer-reviewed funding mechanisms.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 7/27/26 |